Clinical Trials.

For more information about our ongoing Phase 1 clinical study please visit


The Phase 1 study of PMR-116 in patients with advanced solid tumors is being conducted at multiple centers in Australia. This is an open-label, dose escalation study of the safety, pharmacodynamics, and pharmacokinetics of PMR-116 in ascending cohorts to determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. The dose escalation phase will be followed by an expansion phase at the RP2D in patients with evidence of MYC transcription family expression.